Metronidazole is under clinical development by Saptalis Pharmaceuticals and currently in Pre-Registration for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Pre-Registration drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Metronidazole’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Metronidazole overview

Metronidazole (ATI-1501) is under development for the treatment of Clostridium difficile infections. The drug candidate is a proprietary taste-masked liquid suspension reformulation of metronidazole. It is administered orally. Metronidazole acts by targeting DNA.

Saptalis Pharmaceuticals overview

Saptalis Pharmaceuticals, LLC, a pharmaceutical company that develops complex generics and difficult to formulate dosage forms. The company is headquartered in United States.

For a complete picture of Metronidazole’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.